- Field Trip (FTRP) will begin submitting applications on behalf of patients to Health Canada’s Special Access Program (SAP)
- The SAP provides physicians treating patients with “serious or life-threatening conditions”
- It was also involved in having Health Canada recognize that treatment-resistant depression
- No assurances can be made that Health Canada will approve any such applications or that such treatments will be provided
- Field Trip Health Ltd. (FTRP) is down 1.07 per cent, trading at C$2.78 at 11:14 am EST
Field Trip Health (FTRP) will begin submitting applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy.
The applications will be made through Health Canada’s Special Access Program (SAP).
This follows amendments to the SAP announced in the Canada Gazette on January 5, 2022, which have enabled physicians in Canada to make applications to Health Canada for access to “restricted drugs”, including psilocybin and MDMA.
The SAP provides physicians treating patients with “serious or life-threatening conditions” with the ability to request access to drugs that have not yet been approved for sale in Canada when conventional therapies have failed, are unsuitable, or unavailable.
Prior to the amendments, restricted drugs such as psilocybin and MDMA were not accessible through SAP.
Field Trip, which presently operates three Field Trip Health Centers in Canada (Toronto, Vancouver and Fredericton), eight in the United States and one in the Netherlands, was actively involved in providing feedback and commentary to Health Canada on the proposed revisions to the SAP during the 60-Day Public Comment Period.
It was also involved in having Health Canada recognize that treatment-resistant depression, as well as mental health and central nervous conditions such as cluster headaches and migraines, will be considered “serious or life-threatening conditions” for purposes of the SAP.
“Since the opening of our first Field Trip Health Center in Toronto in 2020, we’ve helped people around the world experience relief from suffering and find joy, wonder and fulfilment through our psychedelic therapies,” said Hannan Fleiman, President of Field Trip.
“[…] providing psilocybin-assisted therapies at our location in The Netherlands, we feel there is no organization in the world more qualified than Field Trip to help Canadians access the SAP for these life-changing therapeutics,” added Fleiman.
While Field Trip intends to make applications on behalf of certain Canadians to access psilocybin and MDMA-assisted therapies through the SAP, no assurances can be made that Health Canada will approve any such applications or that such treatments will be provided.
“It has always been a central thesis to our business model that legal access to psychedelic-assisted therapies using psilocybin and MDMA would happen much sooner than most people would have expected,” added Ronan Levy, Field Trip’s Executive Chairman.
Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules.
Field Trip Health Ltd. (FTRP) is down 1.07 per cent, trading at C$2.78 at 11:14 am EST.
